In this foundational pharmacology lecture, we explore how Angiotensin II (Ang II) contributes to cardiovascular hypertrophy and pathological remodeling, with a focus on the cellular mechanisms, extracellular matrix alterations, and hemodynamic effects. Based on Goodman & Gilman's authoritative text, this lecture outlines how Ang II directly impacts cardiac myocytes, vascular smooth muscle cells, and fibroblasts, and how it indirectly promotes remodeling through aldosterone and mineralocorticoid receptor activation.
We also contrast physiological versus pathological hypertrophy, highlighting the clinical implications of chronic Ang II signaling and the partial role of mineralocorticoid receptor antagonists in mitigating disease progression.
Ideal for students and practitioners revisiting cardiovascular pharmacology or learning it for the first time.
Objective:
- By the end of this talk, participants will be able to:
- Identify the key cardiovascular cell types affected by Angiotensin II.
- Describe how Ang II induces cardiac myocyte hypertrophy and promotes vascular smooth muscle cell proliferation and ECM production.
- Explain the role of aldosterone and mineralocorticoid receptor activation in extracellular matrix remodeling.
- Differentiate between the direct cellular effects and hemodynamic effects of Ang II on cardiovascular structure.
- Discuss why pathological remodeling induced by Ang II increases cardiovascular morbidity and mortality, and how pharmacologic interventions can help mitigate this process.
- Contrast pathological (e.g., pressure overload) and physiological (e.g., exercise-induced) cardiac hypertrophy in terms of sarcomere arrangement, capillary density, and reversibility.
Faculty
In addition to the presenter, following authors may have helped with the content writing, review,
or approval:
CME, CE, CEU and Other Credit Types:
ACCME Accreditation Statement
The DrBeen Corp is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to
provide continuing medical education for physicians.
AMA Credit Designation Statement
The DrBeen Corp designates this enduring material for a maximum of 0.75 AMA PRA Category 1
Credits™.
Physicians should claim only the credit commensurate with the extent of their participation in the
activity.
Disclosure Information
In accordance with the disclosure policies of DrBeen Corp and the ACCME (Accreditation Council for
Continuing Medical Education), we are committed to upholding principles of balance, independence,
objectivity, and scientific rigor in all of our Continuing Medical Education (CME) and Continuing
Education (CE) activities. These policies include the careful management and mitigation of any relevant
financial relationships with organizations that are not eligible.
All members of the Activity Planning Committee and presenters have disclosed their relevant financial
relationships. The DrBeen Corp CE Committee has thoroughly reviewed these disclosures and determined
that these relationships are not deemed inappropriate in the context of their respective presentations.
Additionally, they are found to be consistent with the educational objectives and the integrity of the
activity.
| Faculty |
Disclosures |
|
Author declares no conflict of interest. |
Write A New Comment
1 Comments
dr.med.o.aydogmus@*.com
Sep 24 2025, 4:35 pm